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As the COVID-19 crisis moves to its next phase, from ‘acute to chronic’ as it were, it 
is important to note that a variety of immune modifier medicines are now being 
proposed or actively trialled in pursuit of a novel effective intervention for early 
through to poor prognosis coronavirus infection. Such imaginative and creative 
approaches are to be welcomed. Given the current mathematical models of COVID-
19 pandemic resolution, it seems that this may be a lengthy scenario. In the meantime, 
some disease-modifying antirheumatic drugs (DMARD) are being used on a 
presumptive basis, for understandable compassionate reasons, though not always 
based on robust medical evidence. One consequence of widespread uptake of 
DMARD use in COVID-19 is that drug availability may be diminished and thereby 
hamper the management of existing immune-mediated inflammatory diseases and 
particularly rheumatic and musculoskeletal diseases (RMDs). Many people with 
RMDs are reliant on such DMARDs to retain their well-being and loss of therapeutics 
may lead potentially to flare, and disease progression. Mendel et al provide us with 
important evidence of hydroxychloroquine shortages in Canada provided via a survey 
of Canadian rheumatologists.1 They are to be commended for seeking evidence of the 
same. This aligns well with numerous similar reports emerging across European 
countries. The European League Against Rheumatism is committed to ensuring 
equitable access to the medicines necessary to optimally treat RMDs during the 
COVID-19 pandemic.2 This is especially the case when as yet, few or no randomised 
controlled data support the use of immune modifiers in the management of COVID-
19. Thus, while we are supportive of high-quality clinical trial medicine and indeed 
are hopeful that successful outcomes will emerge in pursuit of a solution for COVID-
19, we prefer that the use of agents such as hydroxychloroquine is reserved in the 
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